Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

被引：0
|
作者：
Jürgen Wollenhaupt
Eun-Bong Lee
Jeffrey R. Curtis
Joel Silverfield
Ketti Terry
Koshika Soma
Chris Mojcik
Ryan DeMasi
Sander Strengholt
Kenneth Kwok
Irina Lazariciu
Lisy Wang
Stanley Cohen
机构：
[1] Struenseehaus,Rheumatologie Hamburg
[2] Seoul National University,undefined
[3] University of Alabama at Birmingham,undefined
[4] Healthpoint Medical Group,undefined
[5] Pfizer Inc,undefined
[6] Pfizer Inc,undefined
[7] Pfizer Inc,undefined
[8] Pfizer Inc,undefined
[9] IQVIA Canada,undefined
[10] Metroplex Clinical Research Center and University of Texas Southwestern Medical Center,undefined
来源：
Arthritis Research & Therapy | / 21卷
关键词：
Rheumatoid arthritis; Tofacitinib; Long-term extension;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Wollenhaupt, Juergen
    Lee, Eun-Bong
    Curtis, Jeffrey R.
    Silverfield, Joel
    Terry, Ketti
    Soma, Koshika
    Mojcik, Chris
    DeMasi, Ryan
    Strengholt, Sander
    Kwok, Kenneth
    Lazariciu, Irina
    Wang, Lisy
    Cohen, Stanley
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [2] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
    Pope, Janet E.
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Chapman, Douglass
    Haraoui, Boulos
    [J]. ACR OPEN RHEUMATOLOGY, 2019, 1 (02) : 73 - 82
  • [3] Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
    Curtis, Jeffrey R.
    Wollenhaupt, Juergen
    Chatzidionysiou, Katerina
    Tas, Sander W.
    Wang, Lisy
    Shi, Harry
    Montoro, Maria
    Neregard, Petra
    Dahl, Palle
    Tsekouras, Vassilis
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [4] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Wood, Susan P.
    Terry, Ketti K.
    Nakamura, Hiroyuki
    Ohno, Yukako
    Gruben, David
    Benda, Birgitta
    Wang, Lisy
    Riese, Richard
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993
  • [5] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION UP TO 6 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K. K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 259 - 259
  • [6] PERSISTENCE OF TOFACITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES UP TO 7 YEARS
    Pope, J.
    Keystone, E.
    Jamal, S.
    Wang, L.
    Fallon, L.
    Woolcott, J.
    Lazariciu, I.
    Haraoui, B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 245 - 245
  • [7] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years
    Pope, Janet
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Haraoui, Boulos
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [8] Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment
    Sandborn, William J.
    Lawendy, Nervin
    Danese, Silvio
    Su, Chinyu
    Loftus, Edward V., Jr.
    Hart, Ailsa
    Dotan, Iris
    Damiao, Aderson O. M. C.
    Judd, Donna T.
    Guo, Xiang
    Modesto, Irene
    Wang, Wenjin
    Panes, Julian
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 464 - 478
  • [9] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years.
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Riese, R.
    Wang, L.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S375 - S375
  • [10] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
    Brunner, Hermine, I
    Akikusa, Jonathan D.
    Al-Abadi, Eslam
    Bohnsack, John F.
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant S.
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rodriguez, Juan Cruz Rizo
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Posner, Holly
    Wouters, Ann
    Chang, Cheng
    White, Claire
    Kanik, Keith
    Liu, Shixue
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2024,
12345